V

    Virax Biolabs Group Limited Ordinary Shares (VRAX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.82
    +0.00 (+0.00%)

    Market Cap: $2.25M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-1.75
    Range$-1.75 - $-1.75
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$0.00+100.0%
    30d ago$0.00+100.0%
    7d ago$0.00+100.0%
    Current$-1.75
    Revenue Consensus
    $0
    Range$0 - $0
    0 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Sep 26EST
    		-$-1.75---
    Jun 26
    		$N/A$-1.75N/ABeat-
    Mar 26
    		$N/A$-1.75N/ABeat-
    Dec 25
    		$N/A$-2.50N/ABeat-
    Sep 25
    		$-0.49$0.00N/AMiss-1533.3%
    Jun 25
    		$-0.76$0.00N/AMiss-
    Mar 25
    		$N/A$-8.25N/ABeat-
    Sep 24
    		$-0.89$0.00N/AMiss-
    Jun 22
    		$-0.03$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.05EV/EBITDA0.42x
    Price/FCF-0.09xFCF Yield-1152.32%
    Profitability
    Profit Margin0.00%Operating Margin-35265.00%
    ROE-78.60%ROIC-173.29%
    Financial Health
    Debt/Equity0.01xInterest Coverage-96.85x
    Current Ratio9.97xQuick Ratio9.90x
    Trading Statistics
    Beta1.34Avg Volume959.50K
    52-Week High$21.7552-Week Low$2.50

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.98
    SMA 20$2.92
    SMA 50$3.24
    SMA 200$5.73
    EMA 10$2.92
    EMA 20$2.98
    EMA 50$3.32
    EMA 200$7.08

    MACD

    Line: -0.11Signal: -0.13Hist: 0.02

    ADX

    ADX: 43.0+DI: 26.5-DI: 12.0

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down20.0
    PSAR$4.23

    Bollinger Bands

    Upper Band$3.27
    Lower Band$2.58
    %B Position2379%(Upper)
    Band Width0.35

    RSI (14-Day)

    Neutral
    44.8

    Momentum Oscillators

    Stoch %K9.5
    Stoch %D9.4
    Williams %R-93.0
    ROC (10d)0.4%
    Momentum0.01
    CCI (20d)-50.7
    MFI (14d)95.1

    Volatility Measures

    ATR (14d)$0.48(17.1%)
    StdDev (20d)0.17
    Hist Vol89.3%(High)

    Volume Flow

    VWAP$2.84
    OBV1.9B
    AD Line293.5B
    CMF (20d)-0.464

    Volume Metrics

    Avg Vol (20d)981.1K
    Vol Ratio0.0x(Low)
    VWMA (20d)$3.17

    Pivot Points

    R3$3.12
    R2$3.03
    R1$2.93
    Pivot Point$2.84
    S1$2.73
    S2$2.64
    S3$2.54

    Advanced Oscillators

    TSI-8.27
    Ultimate Osc36.2
    KST-65.25

    Financial Data

    QuarterJun 2026Sep 2025Jun 2025Sep 2024Jun 2024Sep 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021
    Total Revenue$12,423$1,608$1,378$4,953$79,919$76,500$2,801$2,801$5,760$-92,865$-92,865$30,955
    Cost of Revenue$4,733$217,022$47,971$11,427$39,847$65,982$4,284$4,284$5,642$99,940N/A$33,313
    Gross Profit$7,690$-215,414$-46,593$-6,474$40,072$10,518$-1,483$-1,483$118$-192,805N/AN/A
    Operating Expenses$6.41M$2.37M$3.24M$2.87M$3.83M$2.72M$4.29M$4.29M$1.44M$1.17M$436,686$173,143
    R&D$3.74M$1.38M$1.05M$726,412$1.15M$409,295$300,487$300,487$96,622$325,646$0$30,055
    SG&A$2.67M$0$2.18M$2.15M$2.32M$2.27M$4.02M$4.02M$1.29M$831,536$324,984$128,720
    Operating Income$-6,399,730$-2,585,475$-3,284,006$-2,878,891$-3,790,250$-2,706,220$-4,292,190$-4,292,190$-1,440,580$-1,166,940N/AN/A
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$61,772$30,991$32,588$25,591$16,764$10,114$5,860$5,860$9,608$1,294$0$0
    Income Before Tax$-5,932,424$-2,616,867$-3,310,668$-2,893,225$-3,824,916$-2,914,204$-4,003,977$-4,003,977$-1,453,786$-1,174,830$0$0
    Income Tax Expense$-900,240$-273,594$0$-136,661$-1,031$-4,551$-4,282,280$-4,282,280$-1,450,751$16,647$0$0
    Net Income$-5,023,750$-2,338,771$-3,304,820$-2,756,427$-3,823,885$-2,909,652$-4,013,883$-4,013,883$-1,443,611$-1,156,411$-427,395N/A
    EBITDA$-5,509,423$-2,369,174$-3,139,405$-2,766,804$-3,722,775$-2,688,500$294,070$294,070$-3,600N/AN/AN/A
    EBIT$-5,870,652$-2,585,875$-3,284,006$-2,878,891$-3,808,155$-2,706,219$-3,998,115$-3,998,115$-1,444,176N/AN/AN/A
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about VRAX

    News

    Virax Biolabs Posts Updated Q3 2026 Investor Presentation

    Virax Biolabs Group Ltd. (VRAX) has released an updated Q3 2026 investor presentation to enhance transparency and provide refreshed insights into the company's performance and outlook. This move aims to support informed investment decisions and maintain investor engagement. The company, a U.K.-based biotechnology firm, continues to comply with U.S. securities regulations as a foreign private issuer.

    TipRanks•8/18/26•
    Somewhat-Bullish

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    This article lists 12 healthcare stocks that experienced significant movement in Thursday's pre-market session. It details the top gainers, including AtaiBeckley, Agape ATP, Liminatus Pharma, GH Research, Virax Biolabs Group, and Kairos Pharma, along with their percentage increases and market values. The article also covers the top losers, such as CDT Equity, Decoy Therapeutics, Entera Bio, GlucoTrack, Exicure, and Alpha Compute, noting their percentage declines and market caps.

    Sahm•7/18/26•
    Neutral

    Virax Biolabs Raises $3.3 Million via Exercise of Investment Options and Issues New Warrants

    Virax Biolabs Group Ltd. (VRAX) raised approximately $3.3 million by allowing an investor to exercise preferred investment options for 548,000 shares at a reduced price of $6.00 per share. In exchange for this immediate cash infusion and price reduction, the company will issue new Series A and B preferred investment options covering 1.64 million shares, contingent on a shareholder-approved increase in authorized share capital. This move aims to strengthen near-term liquidity but introduces potential future equity dilution.

    TipRanks•7/10/26•
    Neutral

    Virax Biolabs Strikes Exclusive Southeast Asia Supply Deal for ImmuneSelect with Fosun Diagnostics

    Virax Biolabs' UK subsidiary has signed an exclusive multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect products, granting access to six Southeast Asian markets. This deal allows for immediate purchase-order-driven sales and phased expansion, with an initial focus on tuberculosis-related research in Thailand. The agreement is a significant commercial milestone for ImmuneSelect, distinct from the company's ViraxImmune diagnostic platform.

    TipRanks•7/10/26•
    Bullish

    Why Did Virax Biolabs Stock Triple In One Session?

    Virax Biolabs Group Ltd. (NASDAQ: VRAX) saw its stock price triple after signing a multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect product line. This agreement expands Virax Biolabs' commercial footprint into six Southeast Asian markets and is expected to drive significant revenue growth, particularly for tuberculosis-related research in Thailand. The company also recently concluded a 1-for-25 share consolidation and shared positive early performance data for its ViraxImmune blood-based test for Long COVID and related post-acute infection syndromes.

    Sahm•7/9/26•
    Bullish

    Frequently Asked Questions About VRAX

    Does VRAX pay dividends?
    Virax Biolabs Group Limited Ordinary Shares (VRAX) does not currently pay a regular dividend.
    What is VRAX's market cap?
    Virax Biolabs Group Limited Ordinary Shares (VRAX) has a market capitalization of $2.25M with a current stock price of $2.82.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In